Danbo Wang
YOU?
Author Swipe
View article: Fuzuloparib with or without apatinib as maintenance therapy in newly diagnosed, advanced ovarian cancer (FZOCUS‐1): A multicenter, randomized, double‐blind, placebo‐controlled phase 3 trial
Fuzuloparib with or without apatinib as maintenance therapy in newly diagnosed, advanced ovarian cancer (FZOCUS‐1): A multicenter, randomized, double‐blind, placebo‐controlled phase 3 trial Open
Although poly(adenosine diphosphate‐ribose) polymerase inhibitors (PARPis) and bevacizumab were approved as first‐line maintenance for advanced ovarian cancer (OC), evidence comparing this combination with PARPi monotherapy, especially in …
View article: pH-responsive 2D niobium carbide nanosheets for targeted circPUM1 siRNA delivery in ovarian cancer therapy
pH-responsive 2D niobium carbide nanosheets for targeted circPUM1 siRNA delivery in ovarian cancer therapy Open
Ovarian cancer progression is closely associated with tumor microenvironment (TME) dysregulation, particularly pathological angiogenesis driven by exosome-mediated crosstalk. Here, we elucidate that ovarian cancer-derived circPUM1 promotes…
View article: Human papillomavirus infection and disease recurrence/persistence after treatment for women of high-grade cervical intraepithelial neoplasia with coexisting vaginal intraepithelial neoplasia
Human papillomavirus infection and disease recurrence/persistence after treatment for women of high-grade cervical intraepithelial neoplasia with coexisting vaginal intraepithelial neoplasia Open
Background Coexistent cervical intraepithelial neoplasia (CIN) and vaginal intraepithelial neoplasia (VaIN) is problematic, posing challenges for patient management. This study focused on the clinical characteristics of coexistent CIN 2/3 …
View article: Role of tumor microenvironment in ovarian cancer metastasis and clinical advancements
Role of tumor microenvironment in ovarian cancer metastasis and clinical advancements Open
Ovarian cancer (OC) is the most lethal gynecological malignancy worldwide, characterized by heterogeneity at the molecular, cellular and anatomical levels. Most patients are diagnosed at an advanced stage, characterized by widespread perit…
View article: CACA guidelines for vulvar malignancies
CACA guidelines for vulvar malignancies Open
Objective The purpose of this study is to provide reference and guidance for the clinical diagnosis and treatment of vulvar malignancies. Method This article sorts out and integrates the contents of vulvar malignancies in the field of trad…
View article: Effects of neoadjuvant chemotherapy on prognosis and platinum resistance of advanced ovarian cancer
Effects of neoadjuvant chemotherapy on prognosis and platinum resistance of advanced ovarian cancer Open
Objective: Primary Debulking Surgery (PDS) combined with platinum-based chemotherapy is the standard therapy for ovarian cancer. Some trials have suggested that neoadjuvant chemotherapy-Intermittent Debulking Surgery(NACT-IDS) can achieve …
View article: IBI310 plus sintilimab vs. placebo plus sintilimab in recurrent/metastatic cervical cancer: A double-blind, randomized controlled trial
IBI310 plus sintilimab vs. placebo plus sintilimab in recurrent/metastatic cervical cancer: A double-blind, randomized controlled trial Open
This work was funded by Innovent Biologics (Suzhou).
View article: Visualize PIM‐1 Protein Function and Its Interaction With PI3K/Akt/mTOR Pathway Regulated by Its Active Sites Through FRET Biosensors
Visualize PIM‐1 Protein Function and Its Interaction With PI3K/Akt/mTOR Pathway Regulated by Its Active Sites Through FRET Biosensors Open
Pro‐viral Insertion site for the Moloney Murine Leukemia virus 1 (PIM‐1) is widely involved in various biological processes and diseases, which is based on its structure and functional sites. However, the relationship between active sites …
View article: Should All Cervical Cancer Patients with Positive Lymph Node Receive Definitive Radiotherapy: A Population-Based Comparative Study
Should All Cervical Cancer Patients with Positive Lymph Node Receive Definitive Radiotherapy: A Population-Based Comparative Study Open
Objective: The optimal initial treatment for lymph node metastases (LNM) cervical cancer remains a subject of controversy. This study aimed to investigate the association between surgery plus postoperative radiotherapy (PORT) and definitiv…
View article: Research advances in signaling pathways related to the malignant progression of HSIL to invasive cervical cancer: A review
Research advances in signaling pathways related to the malignant progression of HSIL to invasive cervical cancer: A review Open
The progression of high-grade squamous intraepithelial lesion (HSIL) to invasive cervical cancer (ICC) is a complex process involving persistent human papillomavirus (HPV) infection and changes in signal transduction regulation, energy and…
View article: Age-specific performance of human papillomavirus E6/E7 mRNA assay versus cytology for primary cervical cancer screening and triage: community-based screening in China
Age-specific performance of human papillomavirus E6/E7 mRNA assay versus cytology for primary cervical cancer screening and triage: community-based screening in China Open
Background In the general population, primary human papillomavirus (HPV) testing is advocated for cervical cancer (CC) screening. HPV E6/E7 mRNA (Aptima HPV, AHPV) assays have garnered considerable traction due to their higher specificity …
View article: Exploratory biomarker analysis in the phase III L-MOCA study of olaparib maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer
Exploratory biomarker analysis in the phase III L-MOCA study of olaparib maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer Open
Background The prospective phase III multi-centre L-MOCA trial (NCT03534453) has demonstrated the encouraging efficacy and manageable safety profile of olaparib maintenance therapy in the Asian (mainly Chinese) patients with platinum-sensi…
View article: Niraparib maintenance therapy using an individualised starting dose in patients with platinum-sensitive recurrent ovarian cancer (NORA): final overall survival analysis of a phase 3 randomised, placebo-controlled trial
Niraparib maintenance therapy using an individualised starting dose in patients with platinum-sensitive recurrent ovarian cancer (NORA): final overall survival analysis of a phase 3 randomised, placebo-controlled trial Open
Zai Lab (Shanghai) Co., Ltd; National Major Scientific and Technological Special Project for "Significant New Drugs Development" in 2018, China [grant number 2018ZX09736019].
View article: High-grade cervical intraepithelial neoplasia co-existing with vaginal intraepithelial neoplasia increased the risk of persistent human papillomavirus infection and residual/recurrent disease after LEEP
High-grade cervical intraepithelial neoplasia co-existing with vaginal intraepithelial neoplasia increased the risk of persistent human papillomavirus infection and residual/recurrent disease after LEEP Open
Purpose Cervical intraepithelial neoplasia (CIN) with co-existent vaginal intraepithelial neoplasia (VaIN) is a challenge in clinical management. This study was aimed to evaluate the association of having co-existent CIN and VaIN with pers…
View article: Correlation of clinicopathological and prognostic characteristics between endometriosis-associated and primary ovarian cancer
Correlation of clinicopathological and prognostic characteristics between endometriosis-associated and primary ovarian cancer Open
Background The main aim of this study was to establish the clinicopathological and prognostic correlations between endometriosis-associated and non-endometriosis-associated primary ovarian cancer, with a view to providing a reference guide…
View article: Durvalumab Plus Carboplatin/Paclitaxel Followed by Maintenance Durvalumab With or Without Olaparib as First-Line Treatment for Advanced Endometrial Cancer: The Phase III DUO-E Trial
Durvalumab Plus Carboplatin/Paclitaxel Followed by Maintenance Durvalumab With or Without Olaparib as First-Line Treatment for Advanced Endometrial Cancer: The Phase III DUO-E Trial Open
PURPOSE Immunotherapy and chemotherapy combinations have shown activity in endometrial cancer, with greater benefit in mismatch repair (MMR)–deficient (dMMR) than MMR-proficient (pMMR) disease. Adding a poly(ADP-ribose) polymerase inhibito…
View article: Oral Selinexor as Maintenance Therapy After First-Line Chemotherapy for Advanced or Recurrent Endometrial Cancer
Oral Selinexor as Maintenance Therapy After First-Line Chemotherapy for Advanced or Recurrent Endometrial Cancer Open
PURPOSE Selinexor inhibits exportin-1 (XPO1) resulting in nuclear accumulation of tumor suppressor proteins including p53 and has clinical activity in endometrial cancer (EC). The primary end point was to assess progression-free survival (…
View article: Fullerene [60] encapsulated water-soluble supramolecular cage for prevention of oxidative stress-induced myocardial injury
Fullerene [60] encapsulated water-soluble supramolecular cage for prevention of oxidative stress-induced myocardial injury Open
A water-soluble cube-like supramolecular cage was constructed by an engagement of six molecules through a hydrophobic effect in the water. The obtained cage could perfectly encapsulate one fullerene C60 molecule inside of the cavity and si…
View article: Supplementary Information from Efficacy and Safety of the Anti–PD-L1 mAb Socazolimab for Recurrent or Metastatic Cervical Cancer: a Phase I Dose-Escalation and Expansion Study
Supplementary Information from Efficacy and Safety of the Anti–PD-L1 mAb Socazolimab for Recurrent or Metastatic Cervical Cancer: a Phase I Dose-Escalation and Expansion Study Open
Research Protocol for the Phase I Clinical Study of the Recombinant Fully Human Anti-PD-L1 Monoclonal Antibody Socazolimab
View article: Data from Efficacy and Safety of the Anti–PD-L1 mAb Socazolimab for Recurrent or Metastatic Cervical Cancer: a Phase I Dose-Escalation and Expansion Study
Data from Efficacy and Safety of the Anti–PD-L1 mAb Socazolimab for Recurrent or Metastatic Cervical Cancer: a Phase I Dose-Escalation and Expansion Study Open
Purpose:This study (ClinicalTrials.gov identifier, NCT03676959) is an open, phase I dose-escalation and expansion study investigating the safety and efficacy of the recombinant, fully human anti–programmed death ligand 1 (PD-L1) mAb socazo…
View article: Appendix Table A1 from Efficacy and Safety of the Anti–PD-L1 mAb Socazolimab for Recurrent or Metastatic Cervical Cancer: a Phase I Dose-Escalation and Expansion Study
Appendix Table A1 from Efficacy and Safety of the Anti–PD-L1 mAb Socazolimab for Recurrent or Metastatic Cervical Cancer: a Phase I Dose-Escalation and Expansion Study Open
Anti-Tumor Efficacy Assessment using iRECIST criteria by IRC Evaluation
View article: Supplementary Information from Efficacy and Safety of the Anti–PD-L1 mAb Socazolimab for Recurrent or Metastatic Cervical Cancer: a Phase I Dose-Escalation and Expansion Study
Supplementary Information from Efficacy and Safety of the Anti–PD-L1 mAb Socazolimab for Recurrent or Metastatic Cervical Cancer: a Phase I Dose-Escalation and Expansion Study Open
Research Protocol for the Phase I Clinical Study of the Recombinant Fully Human Anti-PD-L1 Monoclonal Antibody Socazolimab
View article: Appendix Table A1 from Efficacy and Safety of the Anti–PD-L1 mAb Socazolimab for Recurrent or Metastatic Cervical Cancer: a Phase I Dose-Escalation and Expansion Study
Appendix Table A1 from Efficacy and Safety of the Anti–PD-L1 mAb Socazolimab for Recurrent or Metastatic Cervical Cancer: a Phase I Dose-Escalation and Expansion Study Open
Anti-Tumor Efficacy Assessment using iRECIST criteria by IRC Evaluation
View article: Supplementary Data from Pamiparib Monotherapy for Patients with Germline <i>BRCA1/2</i>-Mutated Ovarian Cancer Previously Treated with at Least Two Lines of Chemotherapy: A Multicenter, Open-Label, Phase II Study
Supplementary Data from Pamiparib Monotherapy for Patients with Germline <i>BRCA1/2</i>-Mutated Ovarian Cancer Previously Treated with at Least Two Lines of Chemotherapy: A Multicenter, Open-Label, Phase II Study Open
Supplementary Data from Pamiparib Monotherapy for Patients with Germline BRCA1/2-Mutated Ovarian Cancer Previously Treated with at Least Two Lines of Chemotherapy: A Multicenter, Open-Label, Phase II Study
View article: Supplementary Figure from Pamiparib Monotherapy for Patients with Germline <i>BRCA1/2</i>-Mutated Ovarian Cancer Previously Treated with at Least Two Lines of Chemotherapy: A Multicenter, Open-Label, Phase II Study
Supplementary Figure from Pamiparib Monotherapy for Patients with Germline <i>BRCA1/2</i>-Mutated Ovarian Cancer Previously Treated with at Least Two Lines of Chemotherapy: A Multicenter, Open-Label, Phase II Study Open
Supplementary Figure from Pamiparib Monotherapy for Patients with Germline BRCA1/2-Mutated Ovarian Cancer Previously Treated with at Least Two Lines of Chemotherapy: A Multicenter, Open-Label, Phase II Study
View article: Supplementary Figure from Pamiparib Monotherapy for Patients with Germline <i>BRCA1/2</i>-Mutated Ovarian Cancer Previously Treated with at Least Two Lines of Chemotherapy: A Multicenter, Open-Label, Phase II Study
Supplementary Figure from Pamiparib Monotherapy for Patients with Germline <i>BRCA1/2</i>-Mutated Ovarian Cancer Previously Treated with at Least Two Lines of Chemotherapy: A Multicenter, Open-Label, Phase II Study Open
Supplementary Figure from Pamiparib Monotherapy for Patients with Germline BRCA1/2-Mutated Ovarian Cancer Previously Treated with at Least Two Lines of Chemotherapy: A Multicenter, Open-Label, Phase II Study
View article: Supplementary Table from Olaparib Maintenance Monotherapy in Asian Patients with Platinum-Sensitive Relapsed Ovarian Cancer: Phase III Trial (L-MOCA)
Supplementary Table from Olaparib Maintenance Monotherapy in Asian Patients with Platinum-Sensitive Relapsed Ovarian Cancer: Phase III Trial (L-MOCA) Open
Supplementary Table from Olaparib Maintenance Monotherapy in Asian Patients with Platinum-Sensitive Relapsed Ovarian Cancer: Phase III Trial (L-MOCA)
View article: Supplementary Data from Pamiparib Monotherapy for Patients with Germline <i>BRCA1/2</i>-Mutated Ovarian Cancer Previously Treated with at Least Two Lines of Chemotherapy: A Multicenter, Open-Label, Phase II Study
Supplementary Data from Pamiparib Monotherapy for Patients with Germline <i>BRCA1/2</i>-Mutated Ovarian Cancer Previously Treated with at Least Two Lines of Chemotherapy: A Multicenter, Open-Label, Phase II Study Open
Supplementary Data from Pamiparib Monotherapy for Patients with Germline BRCA1/2-Mutated Ovarian Cancer Previously Treated with at Least Two Lines of Chemotherapy: A Multicenter, Open-Label, Phase II Study